Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07575932 · ClinicalTrials.gov registry record · Phase 2
A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)
A Phase 2 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 872
- Enrollment target
NCT07575932: Recruiting Phase 2 study, sponsored by Pfizer.
NCT07575932 is a Phase 2 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 872 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (556% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07575932, a Phase 2 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 872 participants
- Enrollment target
Study Summary
This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).
Interventions
- DRUG Placebo
- DRUG PF-08653944
- DRUG PF-08653945
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 872 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2028-01-05 |
| Phase | Phase 2 |
What NCT07575932 shows while recruiting
NCT07575932 is an interventional study that assigns participants to a tested intervention. The registered 872 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (556% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07575932 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07575932 about?
NCT07575932 is a clinical study titled "A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)". This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).
What is the current status of trial NCT07575932?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 872 participants. The study started on 2026-05-11. Estimated completion is 2028-01-05.
What interventions are being tested in trial NCT07575932?
The interventions under investigation include: Placebo (DRUG), PF-08653944 (DRUG), PF-08653945 (DRUG).
Who is sponsoring clinical trial NCT07575932?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07575932's enrollment target sits among peer trials
872 33rd of 2000 higher than 1,968 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04097145 · 870 participants · NA
Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial
- NCT06822790 · 869 participants · Phase 3
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
- NCT06077760 · 868 participants · Phase 3
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
- NCT07076199 · 877 participants · Phase 3
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI